Background
Breast cancer is one of the most common malignant tumors that has serious effects on the health of women worldwide [
1,
2]. Triple-negative breast cancer (TNBC), one subtype of breast cancer, lacks estrogen receptor (ER), progesterone receptor (PR), and expresses low levels of human epidermal growth factor receptor 2 (HER-2) and accounts for approximately 15–20% of all breast carcinomas [
3‐
5]. TNBC is characterized by higher rates of relapse, greater metastatic potential, and shorter overall survival compared with other major breast cancer subtypes [
4,
5]. Therapeutic methods for TNBC patients usually include surgery, chemotherapy, radiotherapy, and immunotherapy [
6‐
9]. Clinically, although significant progress in the treatment of TNBC over the last decade, recurrence and metastasis remain the principal causes of mortality in patients with this disease [
10,
11]. Therefore, elucidating the potential molecular mechanisms underlying TNBC progression is of great significance to provide promising novel treatment targets and prognostic biomarkers.
In recent years, the potential role of long non-coding RNAs (lncRNAs) has attracted increasing attention in different kinds of cancers. LncRNAs are commonly defined as a class of RNA molecules with a length of more than 200 nucleotides and little or no coding capacity [
12]. LncRNAs are abnormally expressed in many tumors and closely associated with prognosis of tumor patients [
13]. Various studies reported that lncRNAs are responsible for human tumorigenesis and cancer progression by functioning either as oncogenes or tumor suppressors [
14‐
16] and play pivotal roles in tumor cell growth, differentiation, invasiveness, metastasis, anti-apoptosis, and drug resistance [
17‐
19]. For example, long non-coding RNA SNHG12 promotes tumor progression and sunitinib resistance in renal cell carcinoma [
20]. LncRNA CASC2 inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation and migration by regulating the miR-222/ING5 axis [
21]. Previous reports have shown that lncRNAs are involved in the regulation of gene expression through a multitude of mechanisms depending on their subcellular localization. The cytoplasmic lncRNAs are most commonly reported to function as competing endogenous RNAs (ceRNA) to regulate gene expression. For example, long non-coding RNA NEAT1 promotes ferroptosis by modulating the miR-362-3p/MIOX axis as a ceRNA [
22]. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway [
23]. On the other hand, the nuclear lncRNAs could regulate gene expression by participating in several biological processes, such as chromatin organization, nuclear structure organization, severing as transcriptional and post-transcriptional regulators, and acting as scaffolds for TFs [
24,
25]. Given the abundant quantities and diversified regulatory mechanisms of lncRNAs, more efforts are needed to better understand the biological functions and molecular mechanisms of lncRNAs in TNBC and provide information for improving the treatment and prognosis of TNBC.
In the present study, we aimed to explore the function and underlying mechanisms of a novel identified lncRNA, MIDEAS-AS1, in TNBC. We discovered that MIDEAS-AS1 were markedly reduced in breast cancer according to GEO and TCGA databases, which was further confirmed in our cohort. Further, we compared the expression of MIDEAS-AS1 in distinct subtypes in breast cancer, and MIDEAS-AS1 was significantly decreased in TNBC. Moreover, low MIDEAS-AS1 expression was associated with poor prognosis of patients with TNBC. Using in vitro and in vivo experiments, we further demonstrated that MIDEAS-AS1 could inhibit the progression and metastasis of TNBC through interacting with MATR3 to upregulate the transcription of NCALD and subsequently inhibited the NF-κB signaling pathway. These findings indicated that MIDEAS-AS1 might function as a tumor-suppressor lncRNA with potential as a diagnostic/prognostic marker and may offer a novel target for the treatment of patients with TNBC.
Materials and methods
Tissue samples
Human breast cancer tissues and adjacent non-tumor tissues were obtained from patients at the Qilu Hospital. Written informed consent was provided by all patients, and the study was achieved approval by the Ethical Committee on Scientific Research of Shandong University Qilu Hospital (IRB number, KYLL-2016(KS)-140).
Cell cultures
All cell lines were bought from American Type Culture Collection (ATCC, Manassas, VA). MDA-MB-231, MDA-MB-468 and HEK293T cells were cultured with DMEM. The above media contained 100 U/ml penicillin, 100 μg/ml streptomycin, 10% fetal bovine serum (Cell-Box, HK, China) and were cultured with 5% CO2 in a humidified cell-culture incubator at 37 °C.
Breast cancer organoids
Tissues obtained was minced and then, placed into 50 ml conical tube containing 20 ml Advanced DMEM/F-12 (Gibco, CA, USA) which was supplemented with 1× Glutamax, 10 mM HEPES (Invitrogen, Texas, USA), 1 mg/ml BSA (BasalMedia, Shanghai, China), 1× Primocin (InvivoGen, Texas, USA) and 1 mg/ml collagenase (Sigma-Aldrich, MO, USA), 0.01 mg/ml Hyaluronidase (Sigma-Aldrich, MO, USA), 10 μmol Y-27632 (Sigma-Aldrich, MO, USA). Tubes containing minced tissue and collagenase were digested on a 37 °C constant temperature shaker for about 1.5 h. After digestion, filter with 100 μm cell strainer filtration, cell filtrate was enriched by centrifugation at 300 g, 4 °C, at low-speed horizontal-refrigerated centrifuge and washed with cold Advanced DMEM/F-12 twice. Isolated cells were uniformly mixed with Cultrex RGF Basement Membrane Extract Type 2 (R&D Systems, MN, USA). A 50 μl drop of this suspension was placed in center of a well in an uncoated 48 well plate and allowed to harden for 30 min at 37 °C. Finally, each well was added 350 μl of human organoid medium contained Advanced DMEM/F-12 which was supplemented with 1× Primocin (Invitrogen, Texas, USA), 10 mM HEPES, 1× Glutamax, 1× B27 (Gibco, CA, USA), 100 ng/ml Nrg1 (PeproTech, NJ, USA), 100 ng/ml Noggin (PeproTech, NJ, USA), 50 ng/ml EGF (PeproTech, NJ, USA),500 ng/ml Human R-spondin-1 (PeproTech, NJ, USA), 500 nM A83-01 (Tocris Bioscience, MN, USA),5 μmol Y-27632, 5 mM Nicotinamide (Sigma-Aldrich, MO, USA), 3 μmol SB202190 (Sigma-Aldrich, MO, USA), 10 nM Prostaglandin E2 (Sigma), 1.25 mM n-Acetyl Cysteine (Sigma-Aldrich, MO, USA). Organoids were maintained in 37 °C humidified atmospheres under 5% CO2. Medium was changed every 3–4 days, and organoids were passaged using TrpLE Express (Invitrogen, Texas, USA) approximately every 2–4 weeks.
Cell transfection
The small interfering RNAs targeting MIDEAS-AS1, MATR3, NCALD and the scrambled oligonucleotides (NC; 20–50 nM) were purchased from GenePharma (Shanghai, China). Full sequence of MIDEAS-AS1, MATR3, NCALD complementary DNA (cDNA) was amplified by PCR and then, inserted into the vector pcDNA3.1-GFP (abbreviated as “pcDNA3.1”) or pEnter (WZ Biosciences, Jinan, China) to construct pcDNA3.1/MIDEAS-AS1, pcDNA3.1/NCALD, pEnter/MATR3 plasmids. Empty vector (pcDNA3.1, pEnter) was regarded as the control. Using Lipofectamine 2000 (Invitrogen, Texas, USA), all vectors were transfected into breast cancer cells. After 24 h of transfection, cells were collected for following experiments. The sequences that were used are shown in Additional file
1: Table S1.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted using the RNA-easy Isolation Reagent Kit (Vazyme, Nanjing, China). Reverse transcription from 1 μg RNA to cDNA was performed using the PrimeScript reverse transcriptase reagent kit (Takara, Shiga, Japan). Real-time PCR was performed with SYBR qPCR SuperMix Plus (novoprotein, Suzhou, China) on a QuantStudio 6 Flex Real-Time PCR System. Results were analyzed using the comparative Ct method normalizing to Actin. The primer sequences are shown in Additional file
1: Table S2.
Subcellular fractionation
Separation of nuclear and cytosolic fractions was performed using the PARIS Kit (Invitrogen, Texas, USA) according to the manufacturer’s instructions. Afterward, MIDEAS-AS1, GAPDH (cytoplasmic control) and U6 (nuclear control) in a cytoplasmic fraction or nuclear fraction were detected by qRT-PCR.
RNA immunoprecipitation (RIP)
The RIP experiments were performed strictly with a Magna RIP RNA-Binding Protein Immunoprecipitation kit (Millipore, Burlington MA, USA) according to the manufacturer’s instruction. Each RIP reaction required 100 μl of 1 × 107 MDA-MB-231 cell lysate, and each immunoprecipitation required 5 μg of antibody. The expression of MIDEAS-AS1 in the precipitated of anti-MATR3 and negative control (IgG) was detected by qPCR, and the content in the IgG precipitate was used as a reference. qRT-PCR was performed as described above.
Cell migration and invasion assay
After transfection treatment for 24 h, MDA-MB-231 and MDA-MB-468 were harvested and resuspended in serum-free DMEM medium and seeded into the upper transwell chambers containing 8 μm pores. As for invasion experiment, the cells were seeded in Matrigel matrix-plated chambers. Culture medium supplemented with 20% FBS was added to the lower chamber. After incubation for 20 h for migration and 24 h for invasion at 37 °C, the chambers were fixed with methanol, stained with 0.5% crystal violet. Then, the cells on the upper surface were wiped off and allowed to dry at room temperature. The migrated and invasive cells were counted and photographed under a light microscopy (200×) (Olympus, Tokyo, Japan).
Wound healing experiment
The cells were seeded in 24-well plates at a density of 3.5 × 105 cells per well for MDA-MB-231 and 5 × 105 cells per well for MDA-MB-468. Then, incubated the wells with cell culture medium at 37 °C overnight. When the cells at approximately 90% confluence, an artificial wound was made with a 10-µl sterile pipette tip. The fragments were washed thoroughly with PBS, and the wells were added the serum-free medium, cultured for various amounts of time. MDA-MB-231 were incubated for 24 h, and MDA-MB-468 cells were incubated for 48 h. We used a microscope to detect cell migration near the wound and obtain images. The images were processed using ImageJ software to quantify the open wound area as average open wound area % and a histogram was drawn.
Fluorescence in situ hybridization (FISH)
FISH was performed using the RNA FISH Probe Mix Kit (GenePharma, Shanghai, China) according to the manufacturer’s protocol. Briefly, we placed the cell slides in a 24-well plate, seeded the cells at a density of 1.5 × 105 cells per well, and incubated overnight at 37 °C. The medium was discarded and washed twice with PBS in each well, and 4% paraformaldehyde was added and fixed at the room temperature for 15 min. After blocking, the cells were incubated with the lncRNA probes at 37 °C for 16 h and washed three times with a washing solution for 15 min. Subsequently, we added Hoechst 33342 (Beyotime, Suzhou, China) fluorescent dye solution for 10 min at the room temperature while avoiding light and then, observed the distribution of MIDEAS-AS1 under the Confocal Microscope ZEISS LSM 880 (ZEISS, Berlin, Germany).
Chromatin immunoprecipitation (ChIP)-qPCR assay
ChIP assays were performed using a ChIP assay kit (Cell Signaling Technology, MA, USA) according to the manufacturer’s instructions. Briefly, cells were fixed for 10 min with 1% free formaldehyde and then disrupted in SDS lysis buffer. Chromatin was sonicated by Bioruptor® Pico (Diagenode, Belgium) to shear DNA to an average length ranging from 200 to 1000 bp, as verified by agarose gel electrophoresis. Next, chromatin was immunoprecipitated with anti-Flag (Cell signaling Technology, USA), and normal rabbit IgG was used as the negative control. Final DNA extractions were quantitative-PCR amplified using primer pairs that cover the sequence in the NCALD promoter region (−2000 bp to + 100 bp).
RNA–protein pull-down assays
In vitro transcription of sense, antisense or truncated MIDEAS-AS1 was achieved by T7 RNA polymerase (Thermo Fisher, MA, USA). Subsequently, the product of in vitro transcription was obtained biotin-labeled with PierceTM RNA 3’ End Biotinylation Kit (Thermo Fisher, MA, USA). Washed streptavidin magnetic beads were incubated with 50 pmol of purified biotinylated transcripts at room temperature for 30 min, followed by addition of the whole-cell lysates (20–200 μg) from MDA-MB-231 cells and incubated for 1 h at 4 °C. The beads containing DNA and proteins were then washed and eluted, then beads were boiled, and precipitated protein was separated by SDS-PAGE and detected by Western blotting analysis.
Western blotting
Protein samples were harvested from cell lysates, and the concentration of total protein was measured with a BCA Protein assay kit (Millipore, Burlington MA, USA). Protein were separated by SDS-PAGE and transferred to a PVDF membrane (Millipore, Burlington MA, USA). The membrane was blocked with 5% nonfat milk at room temperature and incubated overnight with specific primary antibodies at 4 °C: rabbit anti-Fibronectin (Proteintech, Wuhan, China), rabbit anti-N-cadherin (Proteintech, Wuhan, China), rabbit E-cadherin (Proteintech, Wuhan, China), rabbit anti-Vimentin (Proteintech, Wuhan, China), rabbit anti-MMP-9 (Cell Signaling Technology, MA, USA), mouse anti-GAPDH (Servicebio, Wuhan, China), rabbit anti-MATR3 (Proteintech, Wuhan, China), mouse anti-Actin (Servicebio, Wuhan, China), rabbit anti-NCALD (Proteintech, Wuhan, China), rabbit anti-TGF-β (Proteintech, Wuhan, China), rabbit anti-p-p65 (Affinity Biosciences, OH, USA), mouse anti-p65 (Proteintech, Wuhan, China), rabbit anti-p-Erk1/2 (Cell Signaling Technology, MA, USA), rabbit anti-Erk1/2 (Proteintech, Wuhan, China), washed with Tween-20/TBS and incubated with horseradish peroxidase-conjugated secondary antibodies for 2 h, followed by enhanced chemiluminescence detection (Vazyme, Nanjing, China), and protein bands were visualized using a ECL detection system (Tanon, Shanghai, China), band density was determined using the ImageJ analyzer software (version 1.48).
Immunofluorescence analysis
The cell coverslips were placed in a 24-well plate, seeded transfected MDA-MB-231 at a density of 1.5 × 105 cells per well, and incubated overnight at 37 °C. Then, the cells were fixed with 4% paraformaldehyde for 15 min at room temperature and blocked with 10% goat serum for 30 min. The cells were incubated with rabbit anti-NCALD (Proteintech, Wuhan, China) at 4 °C overnight. Cells were washed three times in PBS and incubated for 1 h at room temperature with FITC conjugated-goat anti-rabbit antibody (ZSGB-BIO, Beijing, China). After several washes, the cells were added hoechst 3342 (Beyotime, Suzhou, China) fluorescent dye solution, and coverslips were mounted to the slides using fluorescent mounting medium (PROLONG-GOLD, Thermo Fisher Scientific, MA, USA). Coverslips were imaged on the Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan).
Cell proliferation assay
1.5 × 103 transfected cells were seeded into each well of five 96-well plates. The cells were cultured for five consecutive days and added with 20 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Beyotime, Suzhou, China). Afterward, the cells were maintained at 37 °C, 5% CO2 for another 4 h, and the MTT solution was removed, and 100 μl DMSO was added to each well. The 490-nm optical absorption value of each well was obtained, and the proliferation curves were established accordingly by using the GraphPad Prism 8.3.0 software.
In total, 500 cells were plated in a six-well plate and cultured in DMEM medium containing 10% FBS. Medium was changed every three days. MDA-MB-231 cells were cultured for two weeks, and MDA-MB-468 cells were cultured for four weeks. Then, cells were washed once with PBS solution and fixed with methanol for 15 min, and 500 μl of 0.5% crystal violet (Beyotime, Suzhou, China) was added to each well for 30 min. The colonies were imaged and counted.
Cell cycle analysis
Cell cycle analysis was performed using Cell Cycle Staining Buffer (Multi Sciences, Hangzhou, China) following the manufacturer’s protocol. Briefly, transfected cells were digested and washed, and then, resuspended in 500 μl of cell cycle staining buffer for 15 min. The cells were examined on a FACSCalibur (BD Biosciences, CA, USA) within 1 h.
Cell apoptosis assay
For apoptosis analysis, FITC-Annexin-V/7-AAD double staining method was used (BD Biosciences, CA, USA). Transfected cells were collected, washed twice with cold PBS, centrifuged at 1000 rpm 5 min, and the supernatant discarded. Then, resuspended cells in 1× Binding buffer at a concentration of 1 × 106 cell/ml. Transfer 100 μl of solution to a 1.5 ml culture tube, added 5 μl FITC-Annexin V, 5 μl 7-AAD to resuspend the cells, reacted for 15 min at the room temperature in the dark. After staining, added 400 μl of 1× Binding buffer to each tube, the apoptosis percentage were analyzed by FACSCalibur flow cytometer (BD) within 1 h.
Luciferase reporter assay
Sequences containing all length or truncated of NCALD promoter were subcloned into pGL4.26-control vector (Addgene, MA, USA). For the reporter assay, HEK-293 T cells were plated onto 48-well plates, and the pGL4.26-NCALD or pGL4.26-truncated-NCALD, the Renilla luciferase plasmid (pRL-TK) were contransfected with pcDNA3.1, MIDEAS-AS1 overexpression plasmids, si-NC, si-MATR3 using Lipofectamine 2000. Finally, each group of cells was transfected with. After transfection for 48 h, the cells were harvested and assayed with a luciferase reporter assay system (Promega, Madison, WI, USA) according to the manufacturer’s instructions. The results were normalized against Renilla luciferase activity.
BALB/c nude mice (female, 4-week-old) with weights of about 20 g were procured from GemPharmatech (Jiangsu, China) for in vivo study. The transfected cells were injected subcutaneously into mice, and the width and length of formed tumors were monitored every 5 days after injection. Tumor volumes were calculated using the following formula: tumor volume = length × width2 × 0.5. Following 25 days, the nude mice were sacrificed, and the collected tumors were weighed and then, fixed in formalin for immunohistochemical (IHC) staining and Hematoxylin and eosin (H&E) staining. To evaluate the influence of MIDEAS-AS1 on metastasis, the transfected cells were injected into the lateral tail veins of nude female mice (six mice per group). After about 2 months, the mice were sacrificed, and the lungs were collected to evaluate the number of pulmonary metastatic lesions and then, also were fixed for HE staining. The animal experiments were approved by the Ethical Committee on Scientific Research of Shandong University Qilu Hospital.
Immunohistochemistry
Paraffin-embedded tissues sections were deparaffinized and rehydrated with xylene, gradient ethanol (70, 80, 95, 100%) and incubated for 20 min in 3% H2O2 to block endogenous peroxidase activity. After blocking with 10% goat serum and then incubated with 50 μl rabbit anti-Ki67 (Proteintech, Wuhan, China), rabbit anti-MATR3 (Proteintech, Wuhan, China), rabbit anti-NCALD (Proteintech, Wuhan, China) at 4 °C overnight. Subsequently, sections were incubated with an appropriate secondary antibody for 20 min at 37 °C and developed with diaminobenzidine and stained with hematoxylin for 5 min. After each treatment, the sections were dehydrated, cleared, mounted, and viewed under the microscope.
Statistical analysis
Statistical test in this study was performed using GraphPad Prism software 8.3.0 software. Results were expressed as the mean ± standard deviation (SD). The Kaplan–Meier method and log-rank test were used to analyze survival rate. Differences of two or more groups were analyzed using the student’s t-test or one-way/two-way ANOVA. Statistical significance was determined as p < 0.05. All tests were conducted in triplicates.
Discussion
Breast cancer is one of the most common malignancies among women worldwide and is the major cause of most cancer-related deaths. There are several explanations for the high mortality rate of breast cancer, with metastasis of vital organs thought to be the main cause [
37]. As reported in the literature, TNBC is the most challenging subtype of breast cancer with higher rates of relapse and greater metastatic potential compared to other breast cancer subtypes [
4,
38,
39]. Despite the treatment methods for patients with metastatic breast cancer are complicated, the curative effects are unsatisfactory in the clinical practice. Therefore, it is of great significance to investigate the molecular mechanism of TNBC metastasis and identify novel prognostic predictors for accurate diagnosis and prediction of prognosis.
It is well known that lncRNA is abnormally expressed in many different types of cancer and is involved in the regulation of tumor development and progression [
40‐
42]. Recently, various studies have focused on the functions and regulations of lncRNAs to search novel diagnostic and therapeutic targets for cancer treatment. In this study, we explored the potential role and molecular mechanism of MIDEAS-AS1 in TNBC progression. We determined that MIDEAS-AS1 was significantly downregulated in TNBC tissues compared to the non-TNBC tissues, and low expression of MIDEAS-AS1 was associated with poor prognosis in TNBC. Functional studies revealed that MIDEAS-AS1 suppressed proliferation, migration and invasion, metastasis and promoted apoptosis of TNBC cells in vitro, indicating a tumor suppressor role in TNBC. Moreover, MIDEAS-AS1 inhibited TNBC tumor progression and lung metastasis in vivo by xenograft model. However, the regulatory mechanism of MIDEAS-AS1 involved in TNBC progression was still unclear and worthy of further exploration.
It is reported that the localization of lncRNAs within the cell is the primary determinant of their molecular functions [
43]. Increasing evidence suggests that cytoplasmic lncRNAs can regulate gene expression by modulating mRNA stability, translation process or participating in mRNA post-transcriptional regulation as ceRNAs [
19,
44]. Meanwhile, the nuclear lncRNAs also participate in several biological processes, including chromatin organization, and transcriptional and post-transcriptional gene expression, and acting as structural scaffolds of nuclear domains [
24]. Here, we found that MIDEAS-AS1 was mainly located in the nucleus based on cell cytoplasmic/nuclear fractionation and RNA FISH assays. Previous studies have reported that lncRNAs could play important role in transcription by recruiting corresponding proteins [
45,
46]. Therefore, MIDEAS-AS1 might exert its function by recruiting transcription complexes and further enhance or inhibit gene transcription. Then, RNA pull-down followed by mass spectrometry showed the binding potential between MATR3 and MIDEAS-AS1, which was further confirmed by RIP assay. Moreover, we also found that MIDEAS-AS1 and MATR3 were co-localization in TNBC cells through RNA FISH technology combined with immunofluorescence. Subsequently, we identified the specific binding region between MIDEAS-AS1 and MATR3. However, we found that the expression level of MIDEAS-AS1 did not affect the RNA and protein levels of MATR3, making us speculating that MIDEAS-AS1 might regulated the function of MATR3 in TNBC cells.
It is reported that MATR3 is an abundant nuclear protein that binds with DNA and RNA [
47,
48], allowing MATR3 to play crucial roles in RNA splicing and gene transcription [
49‐
51]. To further explore the downstream genes regulated by the MIDEAS-AS1-MATR3 complex, we analyzed the RNA-seq results and 471 DEGs were revealed. Following integration with TCGA database, we finally identified 9 candidate genes as potential direct downstream targets of MIDEAS-AS1 and MATR3. NCALD, a member of the neuronal calcium sensors protein family [
52], caught our attention due to the remarkable changes after MIDEAS-AS1 overexpression or knockdown. Studies have found that NCALD was associated with the prognosis of several cancers, including non-small cell lung cancer, ovarian cancer, colorectal cancer, indicating its clinical potential as a prognostic biomarker [
35,
36]. However, the function role and molecular mechanism of NCALD in breast cancer has not been reported. In this study, we found that NCALD was downregulated in breast cancer tissues. Moreover, the expression of NCALD could be regulated by MATR3 in TNBC cells. Significantly, rescue experiment revealed that MATR3 knockdown attenuated the increasing trend of NCALD expression caused by MIDEAS-AS1 overexpression in TNBC cells. Subsequently, dual luciferase reporter assays and ChIP-qPCR indicated that MIDEAS-AS1 and MATR3 complex could bind to NCALD promoter to regulate NCALD transcription.
We further investigated whether NCALD modulate the functional effect of MIDEAS-AS1 in TNBC. Functional experiments revealed that NCALD overexpression inhibited cell proliferation, migration, and invasion in TNBC cells, suggesting the suppressive functional role of NCALD in TNBC progression. Previous study has reported that the TGF-β, NF-κB and ERK signaling pathways were associated with NCALD expression in epithelial ovarian cancer [
35]. Interestingly, Western blot analysis showed that overexpression of NCALD inhibited the expression of the NF-κB pathway-associated proteins, indicating that NCALD inhibited progression of TNBC possibly by suppressed NF-κB signaling pathway. Furthermore, the rescue experiments showed that NCALD knockdown could partially rescue the proliferation and migration ability of TNBC cells inhibited by overexpression of MIDEAS-AS1. Western blot analysis also revealed that MIDEAS-AS1 and MATR3 could not only affect the NCALD expression, but also significantly modulate the NF-κB signaling pathway. Therefore, our study revealed that MIDEAS-AS1 regulated TNBC progression by recruiting the MATR3 to initiate NCALD transcription and suppressing NF-κB signaling pathways (Fig.
7I).